🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. Lofexidine HCl

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Dependence

    phase 3 small molecule completed

    1 trial

  2. Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin

    Ascendis Pharma Endocrinology Division A/S

    Turner Syndrome (TS), idiopathic short stature (ISS), short stature homeobox containing gene deficiency (SHOX-D), small for gestational age (SGA)

    phase 3 small molecule active

    1 trial

  3. Loncastuximab Tesirine

    ADC Therapeutics SA

    Relapsed Diffuse Large B-Cell Lymphoma

    phase 3 small molecule active

    1 trial

  4. Lonsurf 15 mg/6.14 mg film-coated tablets, FRUZAQLA 1 mg hard capsules, Lonsurf 20 mg/8.19 mg film-coated tablets, FRUZAQLA 5 mg hard capsules

    CERO THERAPEUTICS HOLDINGS, INC.

    metastatic oeso-gastric adenocarcinoma

    phase 3 small molecule active

    1 trial

  5. Lonsurf 15 mg/6.14 mg film-coated tablets, Relatlimab + Nivolumab Fixed Dose Combination (FDC), Lonsurf 20 mg/8.19 mg film-coated tablets, Stivarga 40 mg film-coated tablets

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  6. Loperamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Diarrhea-predominant Irritable Bowel Syndrome

    phase 3 small molecule completed

    1 trial

  7. Loperamide

    Chengdu University of Traditional Chinese Medicine

    Diarrhea-predominant Irritable Bowel Syndrome

    phase 3 small molecule completed

    1 trial

  8. Lorundrostat Placebo Tablets, Lorundrostat, Synacthen 0,25 mg/ml Injektionslösung, Lorundrostat

    Mineralys Therapeutics

    Uncontrolled and Resistant Hypertension

    phase 3 small molecule active

    1 trial

  9. Lorundrostat, Lorundrostat, Synacthen 0,25 mg/ml Injektionslösung, Lorundrostat Placebo tablet, Lorundrostat

    Mineralys Therapeutics

    Hypertension

    phase 3 small molecule active

    1 trial

  10. Losartan

    BRIGHT MINDS BIOSCIENCES INC.

    Glomerulonephritis, IGA

    phase 3 small molecule completed

    1 trial

  11. Losmapimod oral tablet

    Fulcrum Therapeutics

    COVID-19

    phase 3 small molecule terminated

    1 trial

  12. Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)

    United Therapeutics Europe Ltd

    TBI Depression

    phase 3 other completed

    1 trial

  13. Low-dose complex B-vitamins

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hyperhomocysteinemia

    phase 3 other completed

    1 trial

  14. Lu AF35700

    H. Lundbeck A/S

    Treatment-resistant Schizophrenia

    phase 3 small molecule terminated

    1 trial

  15. Lubiprostone

    Takeda

    Irritable Bowel Syndrome With Constipation

    phase 3 small molecule completed

    1 trial

  16. Lubiprostone

    Takeda

    Constipation - Functional

    phase 3 small molecule completed

    1 trial

  17. Lucentis 10 mg/ml solution for injection, FARICIMAB

    Hoffmann-La Roche

    Choroidal neovascularization secondary to pathologic myopia

    phase 3 small molecule active

    1 trial

  18. Lucentis 10 mg/ml solution for injection, Ranibizumab

    CuraTeQ Biologics s.r.o

    wet macula degeneration

    phase 3 small molecule active

    1 trial

  19. Lucerastat

    Lacuna Pharma Pty Ltd

    Fabry disease

    phase 3 small molecule active

    1 trial

  20. Lumacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    6 trials

  21. Lumacaftor Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    phase 3 small molecule completed

    1 trial

  22. Lumacaftor Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

    phase 3 small molecule completed

    1 trial

  23. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria Type 1

    phase 3 small molecule completed

    1 trial

  24. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources